Lir Life Sciences Corp. Completes Acquisition of Lir Life Sciences Inc.

Lir Life Sciences Corp., previously known as Blackbird Critical Metals Corp., has successfully acquired Lir Life Sciences Inc. This acquisition involved the issuance of over 22 million common shares to the previous shareholders of Lir Inc., with trading on the Canadian Securities Exchange resuming under the ticker "SKNY" on November 7, 2025.

Following the acquisition, Dr. Edward Mills, a leader in clinical trials and public health, has been appointed as the new CEO. Dr. Mills, with his vast experience and numerous accolades in clinical research, will focus on the company's development of affordable obesity treatments through transdermal delivery methods.

The company also introduced new leadership, including Mr. Harry Nijjar as CFO and Dr. Mark Dybul as a director. Alongside the acquisition, Lir completed a private placement raising over $1 million to further its strategic initiatives. The name change to Lir Life Sciences Corp. was completed on October 31, 2025.